Global Markets for Treatment and Diagnosis of Sexually Transmitted Diseases

Published - Jan 2013| Analyst - Peggy Lehr| Code - PHM005C
Market Research Report Single User License: $2750 Member Price: FREE

Report Highlights

The global market for treatment and diagnosis of sexually transmitted diseases was valued at $28.2 billion in 2011 and $33.2 billion in 2012. Total market value is expected to reach nearly $52 billion in 2017 after increasing at a five-year compound annual growth rate of 9.3%.

Report Includes

  • An overview of the markets for the diagnoses of and treatments for sexually transmitted diseases, including bacterial vaginosis, candidiasis, chancroid, chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, HIV/AIDS, pediculosis pubis, syphilis, and trichomoniasis.
  • Analyses of global market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017.
  • Identifications of common STDs, citing risk factors, incidence, and mortality for each.
  • Discussion of products on the market.
  • A list of current and potential competitors in the market and their market shares.
  • Comprehensive company profiles of major players in the industry.

Report Scope

This market report organizes information from diverse sources into a cohesive report that includes a disease overview, industry structure, diagnostic products, pharmaceutical products, emerging technology, regulations by region and patents sections.

Analyst Credentials

Peggy S. Lehr holds a Bachelor of Science degree in Journalism from the University of Colorado, Boulder, and a Master of Special Studies degree in Communication from the University of Denver.   Ms. Lehr has worked as a researcher, editor and publisher within the publishing industry for both for-profit and not-for-profit organizations.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at
Note: Reports are discounted or included with certain Memberships. See Membership Options.
Published - Mar-2001| Analyst - Mary Anne Crandall| Code - PHM005B

Report Highlights

  • Sexually transmitted diseases are the most common infectious diseases in the U.S. More than 20 STDs have been identified, affecting more than 13 million men and women each year. The annual comprehensive cost of STDs in the U.S. is estimated to be well in excess of $10 to $18 billion.
  • The total current U.S. market for new therapeutics and diagnostics for sexually transmitted diseases in 2000 reached $6.5 billion at the manufacturers' level. The growing numbers of sexually active teenagers and young adults of baby boomers has driven growth in this market. By 2005, it is anticipated that revenues will likely reach $9.4 billion, growing at an average annual growth rate of 7.8%. The total market for therapeutics and diagnostics for sexually transmitted diseases was dominated by the HIV/AIDS in 2000 with 37.1%.
  • The products used in diagnosis and treatments of STDs are of extreme importance. Some STDs are declining in occurrence, while a number of fatal and highly uncomfortable diseases are proliferating. In the early to mid 1990s demographics helped cause decreasing incidence of some of these diseases. But the latter part of the century, when the children of baby boomers became sexually active has influenced the pendulum in the other direction.


Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report